TickerFacts.

MeiraGTx Holdings plc (MGTX): Revenue

Annual figures by period end, from SEC filings.

$81.39M
Year ended 2025-12-31
$397.50M
Trailing 12 months to 2026-06-30
2023-12-31: $14.02M2024-12-31: $33.28M2025-12-31: $81.39M$81.39M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$81.39M+144.6%2026-03-30, From 2025-01-01
2024-12-31$33.28M+137.4%2026-03-30, From 2024-01-01
2023-12-31$14.02Mn/a2025-03-13, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
MeiraGTx Holdings plc (MGTX)2025-12-31$81.39M+144.6%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$85.21Mn/m
Autolus Therapeutics plc (AUTL)2025-12-31$75.39M+644.9%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$74.68M+26.9%
Compugen Ltd (CGEN)2025-12-31$72.76M+161.1%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$70.00Mn/a
Vir Biotechnology, Inc. (VIR)2025-12-31$68.56M-7.6%
Sutro Biopharma, Inc. (STRO)2025-12-31$102.48M+65.2%
Century Therapeutics, Inc. (IPSC)2025-12-31$109.16Mn/m

Compare MGTX, FDMT, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗